Zhejiang CONBA Pharmaceutical Co Ltd
SSE:600572

Watchlist Manager
Zhejiang CONBA Pharmaceutical Co Ltd Logo
Zhejiang CONBA Pharmaceutical Co Ltd
SSE:600572
Watchlist
Price: 4.68 CNY -2.09% Market Closed
Market Cap: 11.7B CNY
Have any thoughts about
Zhejiang CONBA Pharmaceutical Co Ltd?
Write Note

Zhejiang CONBA Pharmaceutical Co Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zhejiang CONBA Pharmaceutical Co Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Zhejiang CONBA Pharmaceutical Co Ltd
SSE:600572
Accounts Receivables
ÂĄ1.4B
CAGR 3-Years
2%
CAGR 5-Years
-3%
CAGR 10-Years
9%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Accounts Receivables
ÂĄ3.2B
CAGR 3-Years
5%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Accounts Receivables
ÂĄ809.6m
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
15%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Accounts Receivables
ÂĄ6.2B
CAGR 3-Years
0%
CAGR 5-Years
3%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Accounts Receivables
ÂĄ10.1B
CAGR 3-Years
15%
CAGR 5-Years
40%
CAGR 10-Years
27%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Accounts Receivables
ÂĄ98.4m
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang CONBA Pharmaceutical Co Ltd
Glance View

Market Cap
11.8B CNY
Industry
Pharmaceuticals

Zhejiang CONBA Pharmaceutical Co., Ltd. stands as a prominent figure in the vast landscape of China's pharmaceutical industry. This enterprise, established in the economically vibrant province of Zhejiang, has carved its niche through rigorous adherence to research-driven innovation and quality assurance. While the pharmaceutical realm is competitive and challenging, CONBA has made strategic inroads by focusing on both modern medicine and traditional Chinese medicine (TCM). This dual approach has allowed the company to tap into a rich tapestry of healthcare solutions, catering to diverse consumer needs. By leveraging a robust research and development framework, CONBA continues to enhance its portfolio, offering a wide array of medicinal products including prescription drugs, over-the-counter medications, and healthcare supplements. Financially, Zhejiang CONBA thrives through a multifaceted business model. The company's revenue streams are bolstered by its strong domestic market presence alongside its expanding international footprint. It strategically combines manufacturing prowess with an extensive distribution network, ensuring that its products are readily accessible. Moreover, CONBA's commitment to quality and compliance with international regulatory standards has fostered trust and reinforced its brand reputation both within and outside of China. As it continues to evolve, CONBA remains dedicated to harnessing advancements in biotechnology and pharmacology, aiming to sustain profitability while contributing to the global healthcare dialogue.

Intrinsic Value
8.12 CNY
Undervaluation 42%
Intrinsic Value
Price

See Also

What is Zhejiang CONBA Pharmaceutical Co Ltd's Accounts Receivables?
Accounts Receivables
1.4B CNY

Based on the financial report for Sep 30, 2024, Zhejiang CONBA Pharmaceutical Co Ltd's Accounts Receivables amounts to 1.4B CNY.

What is Zhejiang CONBA Pharmaceutical Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
9%

Over the last year, the Accounts Receivables growth was 0%. The average annual Accounts Receivables growth rates for Zhejiang CONBA Pharmaceutical Co Ltd have been 2% over the past three years , -3% over the past five years , and 9% over the past ten years .

Back to Top